Archives
-
Fosinopril Sodium: Evidence Boundaries
2026-10-13
The supplied evidence supports describing fosinopril sodium as an ACE inhibitor prodrug, but it does not provide a fosinopril-specific cardiovascular study. A catalpol review offers relevant disease context yet cannot substantiate fosinopril mechanisms, efficacy, or performance in a cardiovascular disease model.
-
What CRISPR Repair Comparisons in Neurons Show
2026-10-13
A 2025 Nature Communications study indicates that postmitotic human neurons repair CRISPR-induced DNA damage differently from genetically matched dividing cells. The evidence supports cell state as an important determinant of editing outcomes, while leaving substantial questions about reproducibility, long-term consequences and applicability beyond the tested models.
-
Vitamin D/VDR and MPA: Evidence Boundaries
2026-10-12
The supplied study supports a VDR-associated role for active vitamin D in endometrial stromal-cell decidualization, but it does not test medroxyprogesterone acetate or establish equivalence between progestin and vitamin D signaling. The main evidence gaps concern direct drug comparisons, physiological relevance, and whether molecular markers predict endometrial receptivity or clinical outcomes.
-
PLAC1 in Clear Cell Renal Cell Carcinoma
2026-10-12
A 2025 Cellular Signalling study links elevated PLAC1 expression with poorer outcomes in clear cell renal cell carcinoma and presents preliminary cellular and computational evidence that PLAC1 may be therapeutically relevant. The findings are hypothesis-generating rather than clinical proof: the reported compound effects were observed in experimental models, and the supplied summary does not establish direct target engagement, in vivo efficacy, or patient benefit.
-
Prednisolone as a Causal Control in ERAD Research
2026-10-10
Prednisolone is more than a standard synthetic glucocorticoid: it can serve as a mechanistic reference for separating glucocorticoid receptor activity from targeted protein degradation. This article interprets the 2026 ERADEC study through that causal lens, clarifying what the evidence supports and where it does not.
-
Perphenazine: Evidence From D2 Biology to Host Defense
2026-10-09
Perphenazine is best understood as a dopamine D2 receptor antagonist with clinically established pharmacology and an emerging, but still preclinical, host-directed antibacterial research profile. This overview compares receptor biology, macrophage findings, reported mitochondrial effects, and evidence related to opioid tolerance suppression. It emphasizes provenance, mechanistic uncertainty, translational boundaries, and why antibacterial activity in experimental systems should not be interpreted as evidence for infectious-disease treatment.
-
PLAC1 in Clear Cell Renal Cell Carcinoma
2026-10-09
A 2025 Cellular Signalling study identifies PLAC1 as an overexpressed, prognostically relevant factor in clear cell renal cell carcinoma and connects its depletion with reduced cancer-associated cellular behavior. The work also uses high-throughput virtual screening to nominate amaronol B and canagliflozin as compounds that lower PLAC1 expression, while leaving target engagement and clinical relevance for future validation.
-
Perphenazine: Research Context and Evidence
2026-10-08
Perphenazine is a dopamine D2 receptor antagonist with established neuropharmacology and emerging research relevance in mitochondrial cell death and host-directed antibacterial responses. This overview compares the evidence, separates reported findings from interpretation, and defines key translational limitations.
-
Atorvastatin and Ferroptosis in Liver Cancer Research
2026-10-08
A source-grounded overview of atorvastatin research in hepatocellular carcinoma, covering its HMG-CoA reductase pharmacology, a 2025 ferroptosis-related prognostic study, preclinical findings, evidence strength, conceptual applications, and important limits on clinical interpretation.
-
WP1066: Contextualizing JAK2/STAT3
2026-10-07
A source-grounded perspective on WP1066 as a JAK2/STAT3 inhibitor, connecting oncology evidence with the context-dependent role of JAK2-STAT3 signaling in macrophage-mediated bone regeneration.
-
TMB in P. vivax Serology: Evidence and Limits
2026-10-07
TMB is a chromogenic signal-generation reagent, not a malaria biomarker. This overview examines how 3,3′,5,5′-Tetramethylbenzidine relates conceptually to recent Plasmodium vivax epitope research, what the 2026 study reported, and why promising serological performance still requires broader validation.
-
Olsalazine Sodium: Reading Transport Evidence
2026-10-06
Olsalazine Sodium is a mesalamine dimer best known for LTB4-related inflammation and cancer research. This evidence-led analysis examines what mosquito xenobiotic-transport findings can—and cannot—reveal about compound disposition, mechanism, and translation to colorectal cancer tumor models.
-
Perospirone: Receptor and Kv1.5 Research Context
2026-10-06
Perospirone, also known as SM-9018 free base, is studied as a serotonin–dopamine antagonist with activity at 5-HT2A, D2, and 5-HT1A receptors. A 2025 in vitro study identified concentration-dependent inhibition of vascular Kv currents in rabbit coronary arterial smooth muscle cells, with evidence implicating Kv1.5 channels. The finding expands the antipsychotic drug mechanism under investigation but does not by itself establish clinical cardiovascular risk or therapeutic relevance.
-
SETD7 Depletion Promotes White Adipose Browning
2026-10-05
A 2026 study identifies SETD7 as a negative regulator of inguinal white adipose thermogenesis, linking its depletion to enhanced beige adipocyte activity through an Adcy7–Sirt1–CREB1 axis. The findings strengthen the rationale for SETD7-focused metabolic disorder research while remaining preliminary for human translation and therapeutic development.
-
Phenothiazines, ROS, and Macrophage Antibacterial Activity
2026-10-05
A 2025 Frontiers in Immunology study reports that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated increases in reactive oxygen species, lysosomal activity, and autophagy. The findings support phenothiazines as host-directed therapy leads, while the study’s cell and animal models do not establish clinical efficacy or explain whether dopamine receptor pharmacology drives the antibacterial phenotype.